Shukra Pharmaceuticals Intrinsic Value

Shukra Pharmaceuticals intrinsic value. Shukra Pharmaceuticals (SHUKRAPHAR) median intrinsic value is ₹32.88 from 10 valuation models (range ₹25–₹164), vs current price ₹82.20 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Shukra Pharmaceuticals shareholding analysis to track promoter, FII and institutional holdings.

Market Price (CMP)
₹82.20
Primary Intrinsic Value
₹25.52
Market Cap
₹361.7 Cr
-60.0% Downside
Median Value
₹32.88
Value Range
₹25 - ₹164
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%

SHUKRAPHAR Valuation Methods Summary — DCF, Graham Number & P/E

Shukra Pharmaceuticals intrinsic value across 10 models vs current price ₹82.20 — upside/downside and value range per method. Browse Shukra Pharmaceuticals annual reports for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹25.52 ₹20.42 - ₹30.62 -69.0% EPS: ₹1.16, Sector P/E: 22x
Book Value Method asset ₹40.91 ₹36.82 - ₹45.00 -50.2% Book Value/Share: ₹20.45, P/B: 2.0x
Revenue Multiple Method revenue ₹81.82 ₹73.64 - ₹90.00 -0.5% Revenue/Share: ₹40.91, P/S: 2.0x
EBITDA Multiple Method earnings ₹164.40 ₹147.96 - ₹180.84 +100.0% EBITDA: ₹76.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹32.88 ₹26.30 - ₹39.46 -60.0% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹24.66 ₹22.19 - ₹27.13 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹24.66 ₹22.19 - ₹27.13 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹164.40 ₹147.96 - ₹180.84 +100.0% ROE: 57.8%, P/E Multiple: 16x
Graham Defensive Method conservative ₹24.66 ₹22.19 - ₹27.13 -70.0% EPS: ₹1.16, BVPS: ₹20.45
Dividend Yield Method dividend ₹24.66 ₹22.19 - ₹27.13 -70.0% DPS: ₹0.01, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

SHUKRAPHAR Intrinsic Value vs Market Price — All Valuation Models

Shukra Pharmaceuticals fair value range ₹25–₹164 vs current market price ₹82.20 across 10 valuation models. For current market price and key ratios, visit Shukra Pharmaceuticals share price screener.

SHUKRAPHAR Intrinsic Value Analysis — Undervalued or Overvalued?

Shukra Pharmaceuticals median intrinsic value ₹32.88, current price ₹82.20 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.

What is the intrinsic value of SHUKRAPHAR?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹32.88 (median value). With the current market price of ₹82.20, this represents a -60.0% variance from our estimated fair value.

The valuation range spans from ₹24.66 to ₹164.40, indicating ₹24.66 - ₹164.40.

Is SHUKRAPHAR undervalued or overvalued?

Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 60.0%.

SHUKRAPHAR Financial Health — Key Ratios vs Industry Benchmarks

Shukra Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 57.8% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 42.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.54x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

SHUKRAPHAR Cash Flow Quality — Operating & Free Cash Flow

Shukra Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹3 Cr ₹-4 Cr Positive Operating Cash Flow 6/10
March 2025 ₹8 Cr ₹8 Cr Positive Free Cash Flow 8/10